These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 1569602

  • 1. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma.
    Liebes L, Walsh CM, Chachoua A, Oratz R, Richards D, Hochster H, Peace D, Marino D, Alba S, Le Sher D.
    J Natl Cancer Inst; 1992 May 06; 84(9):694-9. PubMed ID: 1569602
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
    Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N.
    J Clin Oncol; 1992 Aug 06; 10(8):1310-6. PubMed ID: 1634921
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine.
    Urba WJ, Hartmann LC, Longo DL, Steis RG, Smith JW, Kedar I, Creekmore S, Sznol M, Conlon K, Kopp WC.
    Cancer Res; 1990 May 15; 50(10):2979-86. PubMed ID: 1692252
    [Abstract] [Full Text] [Related]

  • 5. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
    Fujimaki W, Griffin JR, Kleinerman ES.
    Cancer Immunol Immunother; 1993 May 15; 36(1):45-51. PubMed ID: 8422667
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide.
    Landmann R, Obrist R, Denz H, Ludwig C, Frost H, Wesp M, Rordorf C, Towbin H, Gygax D, Tarcsay L.
    Biotherapy; 1993 May 15; 7(1):1-12. PubMed ID: 8068481
    [Abstract] [Full Text] [Related]

  • 7. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
    Asano T, McWatters A, An T, Matsushima K, Kleinerman ES.
    J Pharmacol Exp Ther; 1994 Feb 15; 268(2):1032-9. PubMed ID: 8113959
    [Abstract] [Full Text] [Related]

  • 8. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
    Maeda M, Knowles RD, Kleinerman ES.
    Cancer Commun; 1991 Feb 15; 3(10-11):313-21. PubMed ID: 1722107
    [Abstract] [Full Text] [Related]

  • 9. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid).
    Fujimaki W, Itoh K, An T, Gano JB, Ross MI, Mansfield PF, Balch CM, Augustus LB, Karkevitch DD, Johnston D.
    Cancer Biother; 1993 Feb 15; 8(4):307-18. PubMed ID: 7804372
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
    Asano T, Kleinerman ES.
    J Immunother Emphasis Tumor Immunol; 1993 Nov 15; 14(4):286-92. PubMed ID: 8280710
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.
    Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU.
    J Clin Oncol; 1989 Dec 15; 7(12):1915-25. PubMed ID: 2479721
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES.
    Hematol Oncol Clin North Am; 1995 Aug 15; 9(4):927-38. PubMed ID: 7490249
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.
    Shi F, MacEwen EG, Kurzman ID.
    Cancer Res; 1993 Sep 01; 53(17):3986-91. PubMed ID: 8358727
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes.
    Fogler WE, Fidler IJ.
    Int J Immunopharmacol; 1987 Sep 01; 9(2):141-50. PubMed ID: 3583507
    [Abstract] [Full Text] [Related]

  • 19. Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.
    Maeda M, Asano T, Kleinerman ES.
    Cancer Immunol Immunother; 1993 Aug 01; 37(3):203-8. PubMed ID: 8334682
    [Abstract] [Full Text] [Related]

  • 20. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma.
    Kleinerman ES, Snyder JS, Jaffe N.
    J Clin Oncol; 1991 Feb 01; 9(2):259-67. PubMed ID: 1988574
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.